– Nominating Dr. Prabhavathi Fernandes for election to its Supervisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the invitation to its annual general shareholders’ meeting (“AGM”).
Curetis will hold its AGM on June 16, 2016, at Steigenberger Hotel, Stationsplein Zuid-West 951, 1117 CE Schiphol-Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 13.30 hours CEST; registration starts at 12.30 hours CEST. Also Curetis will be offering electronic pre-voting starting on May 20, 2016 at 08:00 hours CEST.
A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available at http://www.curetis.com/en/investors/share-information/annual-general-meeting.html
The most important resolutions in the agenda of the AGM relate to changes in the Supervisory Board, i.e. the proposed election of new Supervisory Board member Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC, USA) for a three-year term until 2019, the resignation of Dr. Frank Mühlenbeck and the re-election of Dr. Holger Reithinger and Dr. Rudy Dekeyser for another one-year term, respectively.
Also on the agenda is the creation of a new Stock Option Program for the Company and associated changes to the Supervisory Board remuneration, making Supervisory Board members also eligible to such new plan, as well as changes to the Management Board’s Remuneration Policy and Stock Option grants.